Late Breaking Abstract - Exploring optimal management of mild to moderate long-COVID symptoms with OTC medication
<bold>Background:</bold> Long COVID (LC) refers to the sequel or development of new symptoms 3 months after initial COVID-19 infection, affecting more than 17 million people across the WHO European Region. Understanding use of over-the-counter (OTC) medication in LC is crucial due to its global impact and real-world use. <bold>Aims and Objective:</bold> The review aims to guide clinicians in understanding and managing LC symptoms using OTC medication. <bold>Method:</bold> A literature search was conducted upto May 27, 2024 in PubMed & EMBASE using keywords related to LC & OTC medication including naturals <bold>Results:</bold> The lack of a clear clinical definition makes management of LC symptoms challenging. The prevalence of LC varies from 5–30%, affecting major organ systems & patients’ quality of life (QoL). Common symptoms include fatigue, dyspnea, persistent cough, chest pain, myalgia, anxiety, fever. While no specific treatments are approved, OTC medications can help manage symptoms & improve patients QoL. Studies indicate that paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) can help with symptoms like fever or pain lasting ≥3 months after COVID-19. Also, OTC medications and naturals, like mucolytics, antitussives and antihistamines, may benefit for selected LC patients. Promising OTC medications may eventually be incorporated into evidence-based guidelines for managing certain LC symptoms <bold>Conclusion:</bold> LC imposes a significant medical burden on patients, of treatment without guidance affecting their QoL. While no specific treatments are approved, symptomatic management approaches can provide relief. Several OTC medications effectively address mild-to-moderate LC symptoms, including those related to colds, flu, fever and pain
Authors
- Guy Boivin (ORCID: https://orcid.org/0000-0003-3027-4662)
- Preeti Kachroo (ORCID: https://orcid.org/0000-0003-1058-4962)
- Marta Fernandes (ORCID: https://orcid.org/0000-0002-7203-2832)
- William M. Shannon
- Benjamin J. Cowling (ORCID: https://orcid.org/0000-0002-6297-7154)
- Pascal Mallefet
- Pranab Kalita
- Alexandru Mircea Georgescu
Institutions
- Petroleum Geo-Services (United Kingdom) (GB)
- Electro Medical Systems (Switzerland) (CH)
- Pinnacle Clinical Research (US)
- Bridge Pharma (United States) (US)
- Université Laval (CA)
- University of Hong Kong (HK)
Publication Details
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1183/13993003.congress-2024.pa4340
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 0.00